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Objective: Data supporting the utility of percutaneous treatment to maintain vein graft patency have been limited to a
collection of single-institution, retrospective analyses. Using the prospective, multi-institutional PREVENT III database,
we sought to define the outcomes for endovascular vs surgical vein bypass graft revision and to define predictors for the
success or failure of these interventions.
Methods: A nested cohort study of 1404 patients in the PREVENT III trial who underwent infrainguinal vein bypass
grafting for critical limb ischemia was performed to identify those patients who underwent either open surgical or
endovascular graft revision. All patients in PREVENT III were followed up for 1 year from the initial bypass operation.
The following were modeled as end points from the time of the initial open surgical or endovascular revision: freedom
from graft reintervention, occlusion, amputation, and death.
Results: A total of 156 open surgical and 134 endovascular reinterventions were performed, with a mean follow-up after
revision of 193 and 151 days, respectively. Although the demographics for each group were similar, the choice of repair
was influenced by the interval between the index graft placement and the initial revision, with a high percentage of the
early graft revisions treated with an open surgical procedure (0-1 months: 84% open surgical vs 16% endovascular; P <
.001). The primary end point (ie, failure resulting in repeat graft revision, graft occlusion, or major amputation) was
reached in 30.2% of the endovascular and 26.2% of the open surgical individuals, with significant improvements in the
durability of graft revisions noted in the open surgical group (12-month amputation-/revision-free survival of 75% for
the open surgical and 56% for the endovascular group; hazard ratio, 2.2; 95% confidence interval, 0.92-5.26; P  .043).
Furthermore, subgroup analysis revealed this benefit to be most profound within the subset of thrombosed grafts
undergoing salvage (P .006). For revisions performed to treat graft stenosis, early outcomes were similar, with a trend
favoring the open surgical group developing beyond 6 months. Although 80% of open surgical and 64% of endovascular-
revised grafts required no further intervention, endovascular revisions necessitated significantly more reinterventions to
maintain patency. The mean hospital lengths of stay (open surgical, 2.1 days; endovascular, 1.7 days) and quality of life
at completion of the study (VascuQoL: open surgical, 4.72; endovascular, 4.76) were similar between the groups.
Conclusions: Open surgical revision of infrainguinal vein grafts provides an increased freedom from further reinterven-
tions or major amputation, but early success rates for endovascular procedures were similar, particularly for nonoccluded
grafts. With time, endovascular revisions necessitate an increasing number of reinterventions and manifest higher rates of
failure. ( J Vasc Surg 2007;46:1173-9.)Vein graft durability is limited by the development of
intraluminal stenosis and, if untreated, can lead to a reduc-
tion in flow and graft thrombosis.1-3 An array of single-
institution reports has documented primary vein graft pa-
tency rates in the range of 80% at 1 year and 60% at 5
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doi:10.1016/j.jvs.2007.07.049years.4,5 However, recent multi-institutional data have sug-
gested even higher rates of primary failure than previously
reported, with 1-year primary patency rates as low as 61%.6
With increasing experience with endovascular tech-
niques, the last decade has seen a shift in the treatment
approaches for critical vein graft stenosis.7 Open surgical
revision, the previous mainstay for treatment of these le-
sions, has been partially supplanted by percutaneous meth-
ods.8 Support for these minimally invasive approaches,
which offer potentially reduced morbidity and decreased
hospital stays, has been garnered from a series of single-
institution retrospective studies that have suggested equiv-
alent patency rates with both open surgical and endovascu-
lar approaches.9,10 The data collected from the recently
completed PREVENT III trial offer an opportunity to
examine the assumed clinical equivalency between these
two treatment modalities.
The PREVENT III trial was a large multicenter trial
designed to evaluate the efficacy of the pharmacologic
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bypass graft failure.6,11-14 This trial was conducted at 83
North American sites, and 1404 patients undergoing lower
extremity vein bypass grafting for limb-threatening ischemia
were enrolled. Although preimplantation administration of
edifoligide was found to confer no benefit in preventing
vein graft failure, this extensive, prospective database offers
the potential to examine the relative risks and benefits of the
various options available for secondary vein graft revision.
Focusing on the subset of 313 patients requiring bypass
revision, this study evaluates the early clinical performance
and defines the predictors for success or failure of open
surgical and endovascular approaches to maintain vein graft
patency.
METHODS
Trial design. Complete details of PREVENT III, spon-
sored by Corgentech Incorporated (South San Francisco,
Calif) andBristol-Myers Squibb (Princeton,NJ), are provided
elsewhere.6,11,12 In brief, this multicenter, double-blinded,
randomized, placebo-controlled trial was designed to eval-
uate the efficacy of the E2F decoy inhibitor edifoligide in
improving outcomes after vein bypass grafting. Patients
with critical limb ischemia (rest pain, gangrene, or ulcer-
ation) undergoing single-piece or composite autogenous
vein grafting were randomized for ex vivo administration of
edifoligide or placebo before implantation. Exclusion cri-
teria included claudication as the sole indication for bypass,
nonautogenous composite grafts, or in situ vein grafts. The
primary study end point was the time to nontechnical index
graft reintervention or major amputation. All episodes of
index graft occlusion, revision, or amputation were re-
corded through 12 months after implantation.
Data collection. Age, sex, race, medical comorbidi-
ties, medication use, previous ipsilateral bypass procedures,
and institutional setting were recorded upon initial entry
into the study. Renal insufficiency was classified by using
the National Kidney Foundation staging system, in which
stage 1 classifies normal renal function (glomerular filtra-
tion rate 90 mL/min) and stage 5 classifies end-stage
renal disease (glomerular filtration rate15mL/min). The
institutional setting for the index procedure was catego-
rized as academic/United States (for those affiliated with a
residency or medical school), private/United States (for
those independent of established training programs), or
Canadian.
Data recorded at the time of the index procedure
included conduit type, graft size and length, and the loca-
tion of the proximal and distal anastomoses. Conduit types
included great saphenous, small saphenous, or arm veins.
Grafts composed of a composite of these types were in-
cluded in a separate group. Index graft sizes were catego-
rized as less than 3.0 mm, 3.0 to 3.49mm, and greater than
3.5 mm, and graft lengths were classified as less than 40 cm,
40 to 49 cm, 50 to 59 cm, and greater than 60 cm.
Lesion location and graft patency status were docu-
mented at the time of graft reintervention. All adverse
events were collected for 30 days after the index procedure,and serious adverse events, including subsequent hospital
admissions, were collected for the 12-month duration of
the trial. VascuQol, a 25-question disease-specific ques-
tionnaire developed to assess the importance of chronic
limb ischemia, was administered at baseline and 12 months
to assess quality-of-life changes during the course of the
study.
Graft revision. Early graft patency was documented
either by intraoperative imaging or by duplex ultrasonog-
raphy before discharge. Postoperative surveillance of the
graft with duplex ultrasound imaging was performed at 1,
3, 6, and 12 months after the index procedure. A 9-month
study was also obtained if a flow abnormality was observed
at 6 months. A predefined algorithm was used to define the
need for graft revision. These criteria included an angio-
graphic stenosis of greater than 70%, recurrent symptom-
atic critical limb ischemia and an angiographic stenosis of
greater than 50%, severe hemodynamic compromise of the
index limb (ankle-brachial index of 0.4 or a toe pressure
of 30 mm Hg), or a duplex ultrasound study indicating
severe graft stenosis (a peak systolic velocity ratio of3.0 or
a peak systolic velocity of300 cm/s). Angiography (con-
trast or magnetic resonance) was mandated before elective
graft revision, unless contraindicated. Revisions were cate-
gorized as open surgical or endovascular on the basis of the
techniques used during the initial reintervention proce-
dure. The locations of the lesion(s) were abstracted from
these imaging studies and categorized as proximal anasto-
motic, graft body, distal anastomotic, or multiple. Inter-
ventions performed exclusively to treat lesions in the native
artery, proximal or distal to the graft, were excluded from
this analysis.
Statistical methods. Differences in baseline charac-
teristics between open surgical and endovascular graft revi-
sion were assessed with Pearson 2 analysis. The primary
end point of the study was the time from first graft revision
to thrombosis, recurrent stenosis greater than 70%, repeat
intervention, or major amputation. Propensity scoring was
used to generate weights to balance baseline demographic
and comorbid covariates between the open surgical and
endovascular revision groups. Significant interactions be-
tween baseline covariates, identified with a backward selec-
tion logistic regression model, were included to obtain
optimal group predictability. After weighting, all balanced
covariates were substantively and significantly nondifferent
(Table I online only). Upon reweighting, the difference
between open surgical and endovascular revisions for the
primary end point was assessed with proportional hazards
regression. Weighted Kaplan-Meier survival curves were
constructed for subgroup analyses and assessment of pro-
gression to major amputation or death; differences were
evaluated by using a log-rank statistic.
Two multiple logistic regression analyses with back-
ward elimination were used to identify independent predic-
tors for failure of the revision. Age, sex, race, medical
comorbidities, medication use, previous ipsilateral bypass
procedures, institutional setting, and the surgical details of
the index procedure (including conduit type, graft size and
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moses) were evaluated in the regression analysis.
All differences were considered significant with P 
.05. Continuous data variables are presented as mean 
SD. All analyses were performed in SAS 9.1 (SAS Institute,
Cary, NC).
RESULTS
Of the 1404 patients enrolled in the PREVENT III
trial, 313 underwent at least 1 reintervention of their index
graft during the 1-year follow-up period. This comprises
the study population. Of the initial reinterventions, 134
underwent endovascular treatment, 157 underwent open
surgical treatment, and 22 were treated with a combined
open surgical and endovascular approach. Patients receiv-
ing combined interventions were excluded from subse-
quent analyses. The follow-up observation time for the
study population was a mean of 151 days (25th-75th
percentiles, 68-244 days) for the endovascular group and
193 days (25th-75th percentiles, 90-292 days) for the open
surgical group from the first graft revision.
Patient demographics and graft characteristics.
Pertinent demographic variables, defined at the time of
index graft placement, are shown for the endovascular and
open surgical groups in Table II. Among the most interest-
ing observations is the distribution of reinterventions per-
Table II. Patient demographics for endovascular and
surgical revision groups
Variable
Endovascular
(n  134)
Surgical
(n  156) 2
Age (y) 67.6 69.9
Sex 0.85
Male 66% 65%
Female 34% 35%
Race 0.23
Black 17% 12%
White 74% 79%
Hispanic 8% 9%
History of CAD 37% 42% 0.42
History of smoking 82% 78% 0.41
Hypercholesterolemia 47% 42% 0.42
Hypertension 78% 81% 0.52
Diabetes 54% 60% 0.32
Renal insufficiency 0.64
eGFR: stage 1 or 2 62% 54%
eGFR: stage 3 25% 32%
eGFR: stage 4 3% 4%
eGFR: Stage 5 10% 10%
Edifoligide 51% 51% 0.97
Antithrombotic 96% 97% 0.57
Beta-blocker 57% 56% 0.86
Statin 42% 44% 0.67
Previous ipsilateral bypass 31% 30% 0.93
Institutional setting 0.07
Academic 66% 57%
Private 26% 38%
Canadian 8% 5%
CAD, Coronary artery disease.formed at various institutional care settings. Although pa-tients treated at academic medical centers were evenly split
between the endovascular and the open surgical groups,
almost two thirds of the patients treated in the private
sector received an open surgical revision (open surgical,
88/176 [50%] vs 60/95 [63%]; P  .05, academic vs
private, respectively).
Characteristics of the index graft at the time of initial
placement are provided in Table III and demonstrate no
significant influence of conduit type, length, diameter, or
anastomotic locations on the decision to proceed with an
open surgical or endovascular reintervention. Characteris-
tics of the initial reintervention procedure are detailed in
Table IV. Characteristics of the endovascular and
surgical revision groups at the time of the initial graft
revision
Variable
Endovascular
(n  134)
Surgical
(n  156) 2
Patency of index graft 0.39
Patent (stenotic) 115 (86%) 139 (89%)
Occluded 19 (14%) 17 (11%)
Lesion location 0.86
Proximal 25 (19%) 32 (21%)
Body 64 (48%) 69 (44%)
Distal 21 (16%) 29 (19%)
Multiple 24 (18%) 26 (17%)
Time of revision (after graft
placement) (mo) 0.0001
0-1 8 (6%) 41 (27%)
1-3 20 (15%) 30 (20%)
3-12 104 (79%) 79 (53%)
Table III. Graft characteristics of the endovascular and
surgical revision groups at the time of index graft placement
Variable
Endovascular
(n  134)
Surgical
(n  156) 2
Conduit type 0.49
Great saphenous vein 70% 76%
Small saphenous or arm vein 6% 5%
Composite vein 24% 19%
Graft length (cm) 0.03
40 20% 15%
40-50 33% 20%
50-60 15% 26%
60 31% 37%
Graft diameter (mm) 0.07
3.0 5% 11%
3.0-3.5 45% 45%
3.5 49% 40%
Proximal anastomosis 0.14
Common femoral 62% 55%
Superficial femoral 24% 22%
Popliteal 7% 7%
Other 7% 15%
Distal anastomosis 0.12
Popliteal 33% 29%
Tibial 57% 62%
Pedal 5% 8%
Other 4% 1%Table IV. Most grafts were patent at the time of the
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cantly influencing the decision to proceed with open
surgical or endovascular revisions. Similarly, lesion loca-
tion had a limited apparent effect on the type of revision
selected. In contrast, the interval between index graft
placement and the initial revision influenced the type of
revision performed, with a high percentage of the grafts
necessitating early revision treated with an open surgical
procedure (0-1 months: 41/49 [84%] vs 8/49 [16%];
P  .001; open surgical vs endovascular, respectively).
With the potential for these early surgical graft revisions
being undertaken primarily for technical complications
of the index procedure, these 49 grafts were excluded
from subsequent analysis.
Graft revision outcomes. The primary end point (ie,
grafts necessitating revision for stenosis, graft occlusion, or
major amputation) was reached in 33 (30.2%) of the endo-
vascular and 35 (26.2%) of the open surgical cases. The
durability of endovascular and open surgical revisions was
evaluated through the use of a propensity model designed
to adjust for the influence of covariate distribution on this
primary end point. As noted previously, interventions oc-
curring within 1 month of initial placement and revisions
undertaken for graft occlusion were thought to be intrinsi-
cally poor candidates for endovascular intervention and
were excluded from the analysis. Unweighted andweighted
proportional hazards functions displaying the time from
index graft revision to failure are provided in Fig 1. Mar-
ginal improvements in the durability of graft revision were
noted in the open surgical group, with unweighted esti-
mates of 12-month amputation-/revision-free survival of
75% and 56% in the open surgical and endovascular groups,
respectively (hazard ratio, 1.4; 95% confidence interval,
1.05-1.89; P  .054). This difference in outcomes was
maintained in the fully adjusted propensity score model,
with estimated open surgical and endovascular 12-month
survival rates of 68% and 52%, respectively (hazard ratio,
2.2; 95% confidence interval, 0.96-5.56; P  .043).
Kaplan-Meier evaluation of major amputation (Fig 2, A,
online only) and death (Fig 2, B, online only) demon-
strated no significant differences between groups, with
12-month estimates of 90% and 94% for limb salvage and
death, respectively.
Resource utilization and quality of life. The fre-
quency of subsequent reinterventions for the endovascular
and open surgical groups is provided in Fig 3. Overall,
secondary reintervention rates for the endovascular and
open surgical groups were 35% and 23%, respectively, with
the frequency of both single and multiple reintervention
significantly increased after initial endovascular revision
(P  .009).
Despite the inherent differences in the invasiveness of
the each intervention, the length of hospitalization during
the initial graft revision was similar for each group (endo-
vascular, 2.0 1.9 days; open surgical, 2.4 1.5 days; P
.14). The cumulative number of subsequent hospital days,
tabulated from initial graft revision to 12-month study
completion, was also not significantly influenced by thetype of initial revision performed (endovascular, 23.9 
21.1 days; open surgical, 26.6  25.3 days; P  .34).
The effect of these interventions on quality of life was
assessed by using the VascuQoL questionnaire, with global
scores distributed from 1 (worst) to 7 (best). Baseline
scores, preceding initial graft placement, were similar for
each group (endovascular, 2.7  1.1; open surgical, 2.7 
1.0; P .63). Significant improvement in overall quality of
life was observed at completion of the 12-month study
period, and these changes were independent of the type of
revision performed (endovascular, 4.8 1.4; open surgical,
Fig 1. Propensity model evaluation for freedom from subsequent
graft revision or major amputation for open surgical and endovas-
cular treatments. Analysis excludes grafts necessitating early revi-
sion for assumed technical complications and grafts revised after
occlusion. Both unweighted and weighted models suggest a mar-
ginal survival benefit for grafts undergoing open surgical revision
(n  122 for open surgical cases and n  97 for endovascular
cases).4.7  1.5; P  .88).
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of revision on outcomes. Patency status at the time of
reintervention, lesion location, and timing of the initial
revision (Table V) were examined in a post hoc analysis as
potential underlying factors influencing the significant
difference in open surgical and endovascular graft dura-
bility. Subgroup analysis of prerevision patency status
(with 14% of the endovascular and 10% of the open
surgical procedures performed in the setting of index
graft occlusion) is provided in Fig 4. Endovascular revi-
sion of occluded vein grafts was associated with particu-
larly poor outcomes, with Kaplan-Meier estimates of
12-month graft survival of 39% vs 88% in the endovas-
cular and open surgical revised grafts, respectively. Con-
versely, revisions in nonoccluded grafts demonstrated no
statistical difference in early survival after endovascular
or open surgical interventions, although divergence of
these outcomes starting at 7 months suggests a growing
trend toward improved survival in the open surgical
group. Similar analyses to examine the influence of lesion
location (proximal, body, distal, or multiple) and timing
of the revision (0-29 days, 30-89 days, and 90 days)
failed to demonstrate these factors to significantly dis-
criminate outcomes between the endovascular and open
surgical groups.
Multivariate analysis. Multivariable regression analy-
sis using all patient demographic and graft characteristic
variables (Tables II, III, and IV) was performed for
endovascular and open surgical groups separately, to
identify those factors predictive of improved graft dura-
bility for each of these intervention strategies. Results are
provided in Table V, with hazard ratios greater than 1
Fig 3. Reinterventions after initial graft revision. An increased
number of procedures are required to maintain patency after
endovascular interventions (P  .009). The follow-up time in this
study ranged from 0 to 396 days from initial reintervention, with
means of 193 and 151 days for the open surgical and endovascular
groups, respectively.suggesting reduced graft survival in association with thatvariable. Previous infrainguinal bypass procedures and
composite vein conduits were at increased risk in the
endovascular group, whereas the presence of multiple
lesions was a predictor of early failure in the open surgical
group. Timing of the reintervention in the endovascular
group only presented a hazard ratio less than 1, suggest-
ing endovascular revisions performed at earlier times to
be at increased risk for failure. In contrast, statin use and
a history of hypertension were protective from further
interventions in both the open surgical and endovascular
groups.
DISCUSSION
The risk of myointimal hyperplasia leading to nar-
rowing of the vein graft, a reduction in flow, and recur-
rent limb ischemia has been well documented.1-3 Vein
graft revision before graft failure has offered patency
rates approaching those of grafts not necessitating inter-
vention.8,15-17 An understanding of the factors sur-
rounding vein graft revisions has been obtained through
a collection of previous single-institution retrospective
studies.9,10,18,19 Inherent in these studies is the potential
nonuniformity of data collection, the inherent difficulty
in maintaining a large cohort for serial follow-up of
patients, and variability in the threshold for reinterven-
tion of the failing graft. The cohort of patients within the
PREVENT III trial offers a robust data set to examine
the early outcomes surrounding vein graft revision. Stan-
dardized prospective data collection provides precise
characterization of the patients and the index graft. The
defined series of follow-up examinations and duplex
testing ensures reliable outcomes data. Also, the use of
standardized criteria for the definitions of graft stenosis
and triggers for reintervention provides a uniform ap-
proach to this problem. Coupled with the breadth of
centers (private/academic, United States/Canadian) and the
size of the data set, this study offers the potential for unique
and powerful observations related to vein graft revision.
The central focus of this study was an evaluation of the
outcomes of open surgical and endovascular vein graft
revision. Some studies have suggested these intervention
strategies to be equivalent, but they were underpowered to
provide a clear understanding of potential factors that may
have influenced these outcomes.9,10 Other studies have
suggested percutaneous interventions to be inferior to
open surgical revision.18,19 The current data clearly dem-
onstrate that in aggregate, open surgical revascularization
imparts improved graft survival over endovascular interven-
tions. These data are consistent with the observation that
endovascular interventions more frequently require multi-
ple independent procedures to maintain graft patency, thus
suggesting surgical vein graft revision to be more durable.
This is balanced by the perceived benefit of reduced mor-
bidity and mortality that endovascular revision offers over
surgical intervention. Reduced rates of major amputation
and death seem consistent with the results of this study,
although the event rate for both these outcomes was insuf-
ficient for definitive conclusions. Neither hospital length of
es.
ard ra
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benefited by endovascular intervention, was significantly
different between endovascular and open surgical proce-
dures in this study.
Multivariate modeling offers some interesting insight
into factors that may influence outcomes after each type of
intervention. Not unexpectedly for endovascular interven-
tions, previous infrainguinal bypasses and composite con-
duits have an increased and shorter bypasses have a reduced
probability of failure. The hazard ratio related to the timing
of endovascular revisions identifies grafts undergoing later
intervention to have improved durability, a finding consis-
tent with previously published reports.9 Along similar lines,
surgically treated grafts with multiple lesions are associated
with increased failure. A potentially important finding is
related to statin use and improved graft durability after
both endovascular and surgical revision. Recent publica-
tions further support this evolving concept.20 Also of po-
tential interest are the comorbidities that influence the
durability the reinterventions. Hypertension seems to be
associated with reduced failure of both endovascular and
surgical revisions. Although the reason for this observation
is not readily apparent and could relate to confounders such
as other medications not recorded in this database (eg,
angiotensin inhibitors and calcium channel blockers), the
presence of this factor in both models is of interest. Further
studies are required to determine the factors predictive of
durability for vein graft reinterventions.
Although the study has notable strengths, also implicit
are several important limitations. Among the most important
is the limited time frame of the experiment. Although it is
tempting to extrapolate these conclusions to later times, cau-
tion should be taken in this generalization. Also influencing
the study is the lack of detailed information around the revi-
sion events. Not included in the PREVENT III data set was
information related to the specific techniques (eg, the use of
Table V. Multivariate modeling of freedom from reinterv
reintervention
Revision type Factor
Endovascular Previous infrainguinal reconstruction
Conduit type: composite vein*
Proximal anastomosis: SFA†
Time of revision (from index graft placeme
Statin use
Hypertension
Conduit length: 50-60 cm§
Institutional setting: Canadian#
Surgical Multiple stenotic lesions
Statin use
Diabetes
Hypertension
CI, Confidence interval.
Hazard ratios were referenced to the following— *conduit type: single s
§conduit length: 40 cm; and #institutional setting: academic/United Stat
‡Time of revision (days) was modeled as a continuous variable with the hazcutting balloons, cryoplasty, atherectomy, or stents) or com-plications associated with reinterventions—clearly important
components that, if available, would enhance this study.
Finally, the PREVENT III protocol did not provide any
guidelines to investigators regarding the choice of reinter-
vention, and the criteria used by individual surgeons for
selecting endovascular or open surgical procedures are un-
known. Although the propensity score model attempts to
adjust for potential known confounders, many other factors
(eg, lesion length) that are undefined in the database were
likely involved in procedure selection, with a likely effect on
outcomes. Finally, the quality-of-life assessments per-
formed in PREVENT III were designed to examine global
health status in relation to the timing of the index operation
and therefore might not accurately reflect potential differ-
ences in relation to the magnitude of reinterventions that
were performed.
In summary, open surgical revision of infrainguinal vein
grafts provides an increased freedom from further reinter-
ventions or major amputation; however, early success rates
for endovascular procedures were similar, particularly for
nonoccluded grafts. With time, endovascular revisions re-
quire an increasing number of reinterventions and manifest
higher rates of failure. These data support the critical im-
portance of continued ultrasound surveillance after vein
graft revisions.
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covariates before and after propensity model weighting
Variable
Endovascular
(n  98)
Surgical
(n  121) P value
Age
Unweighted 67.62 70.15 .05
Weighted 69.8 68.3 .33
Black race
Unweighted 17.16 12.85 .286
Weighted 14.08 14.89 .92
Sex
Unweighted 33.58 34.64 .84
Weighted 31.07 25.60 .49
Institution
Academic
Unweighted 65.67 57.54 .053
Weighted 63.7 67.78 .71
Canadian
Unweighted 8.21 4.47
Weighted 5.71 3.62
Private
Unweighted 26.12 37.99
Weighted 30.59 28.59
History of coronary disease
Unweighted 36.57 47.49 .05
Weighted 43.74 48.00 .71
Previous ipsilateral bypass
Unweighted 30.60 29.61 .85
Weighted 29.05 40.92 .31
Smoking
Unweighted 82.09 78.77 .46
Weighted 69.10 69.86 .95
Renal insufficiency
eGFR: stage 1 or 2
Unweighted 61.94 54.19 .49
Weighted 61.48 59.62 .98
eGFR: stage 3
Unweighted 24.63 31.84
Weighted 25.78 28.61
eGFR: stage 4
Unweighted 2.99 3.91
Weighted 3.24 2.81
eGFR: stage 5
Unweighted 10.45 10.06
Weighted 9.49 8.96
Diabetes
Unweighted 54.48 59.22 .40
Weighted 67.49 54.70 .24
Hypercholesterolemia
Unweighted 47.01 42.46 .42
Weighted 46.52 60.00 .20
Hypertension
Unweighted 78.36 83.24 .27
Weighted 24.77 75.23 .85
Beta-blockers
Unweighted 57.46 59.22 .75
Weighted 63.52 56.06 .51
Statins
Unweighted 41.79 44.69 .60
Weighted 52.78 53.73 .93
Antithrombotics
Unweighted 95.52 97.21 .42
Weighted 96.36 96.93 .82
Edifoligide
Unweighted 51.49 52.51 .85
Weighted 57.62 66.08 .38Table I. Continued
Variable
Endovascular
(n  98)
Surgical
(n  121) P value
Distal anastomosis
Popliteal
Unweighted 32.84 27.93 .19
Weighted 29.51 35.10 .78
Tibial
Unweighted 57.46 60.89
Weighted 59.76 51.34
Pedal
Unweighted 5.22 9.50
Weighted 7.76 6.67
Other
Unweighted 4.48 1.68
Weighted 2.98 6.88
Proximal anastomosis
Common femoral
Unweighted 61.94 53.63 .13
Weighted 63.21 62.10 .96
Superficial femoral
Unweighted 23.88 24.02
Weighted 23.47 23.71
Popliteal
Unweighted 7.46 7.26
Weighted 6.09 5.12
Other
Unweighted 6.72 15.08
Weighted 7.23 9.06
Graft diameter (mm)
3.0
Unweighted 5.22 10.06 .09
Weighted 15.14 11.44 .84
3.0-3.5
Unweighted 44.78 45.25
Weighted 42.62 47.59
3.5
Unweighted 49.25 40.78
Weighted 41.27 38.71
Conduit type
Great saphenous vein
Unweighted 70.15 75.42 .58
Weighted 72.99 62.90 .60
Small saphenous/arm vein
Unweighted 5.97 5.03
Weighted 4.69 3.62
Composite vein
Unweighted 23.88 19.55
Weighted 22.33 33.47
Graft length (cm)
40
Unweighted 20.15 15.64 .07
Weighted 15.90 12.57 .93
40-50
Unweighted 32.84 21.79
Weighted 23.60 22.65
50-60
Unweighted 14.93 22.91
Weighted 23.81 29.15
60
Unweighted 30.60 36.87
Weighted 36.69 35.63
Lesion location
Proximal
Unweighted 17.91 16.76 .78
Weighted 16.78 15.75 .89
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Variable
Endovascular
(n  98)
Surgical
(n  121) P value
Body
Unweighted 47.76 43.58
Weighted 50.04 54.11
Distal
Unweighted 15.67 16.76
Weighted 18.96 14.22
Multiple
Unweighted 18.66 22.91
Weighted 16.78 15.75Fig 2. online only. Univariate analysis of amputation and death
for percutaneous and surgical interventions. There were trends
toward improved survival and a reduced incidence of major ampu-
tation after percutaneous interventions; however, the event rate is
small, with no significant statistical differences.
